We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+5.28%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$5.14B
AUM Growth
+$467M
(+10%)
Cap. Flow
+$273M
Cap. Flow
% of AUM
5.31%
Top 10 Holdings %
Top 10 Hldgs %
11.46%
Holding
1,074
New
159
Increased
412
Reduced
333
Closed
136
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Philip Morris
PM
|
+$28.6M |
| 2 |
AGN
Allergan plc
AGN
|
+$26.5M |
| 3 |
Toro Company
TTC
|
+$22.4M |
| 4 |
PepsiCo
PEP
|
+$20.4M |
| 5 |
Lockheed Martin
LMT
|
+$17.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuit
INTU
|
+$26.1M |
| 2 |
Wells Fargo
WFC
|
+$19.4M |
| 3 |
Centene
CNC
|
+$17.3M |
| 4 |
Eli Lilly
LLY
|
+$15.8M |
| 5 |
Kroger
KR
|
+$14.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.58% |
| 2 | Financials | 18.08% |
| 3 | Industrials | 12.96% |
| 4 | Healthcare | 11.05% |
| 5 | Consumer Discretionary | 11.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Regions Financial
RF
$26.3B
| $5.21M | 0.1% |
341,994
+89,794
| +36% | +$1.29M |
|
|
IMPV
252
DELISTED
Imperva, Inc.
IMPV
| $5.13M | 0.1% |
118,101
+19,891
| +20% | +$908K |
|
253
Boise Cascade
BCC
$2.74B
| $5.12M | 0.1% |
146,660
+32,540
| +29% | +$988K |
|
254
John Wiley & Sons Class A
WLY
$2.52B
| $5.1M | 0.1% |
95,308
-93,615
| -50% | -$5.02M |
|
|
IPXL
255
DELISTED
Impax Laboratories, Inc.
IPXL
| $5.09M | 0.1% |
250,724
+128,459
| +105% | +$2.46M |
|
256
Curtiss-Wright
CW
$27.7B
| $5.04M | 0.1% |
48,190
-14,095
| -23% | -$1.37M |
|
|
CSOD
257
DELISTED
Cornerstone OnDemand, Inc.
CSOD
| $4.86M | 0.09% |
119,576
+39,426
| +49% | +$1.46M |
|
258
O-I Glass
OI
$1.39B
| $4.78M | 0.09% |
190,130
+59,570
| +46% | +$1.45M |
|
259
Southwest Gas
SWX
$6.74B
| $4.76M | 0.09% |
61,300
+4,750
| +8% | +$376K |
|
260
Xerox
XRX
$337M
| $4.74M | 0.09% |
142,250
+90,476
| +175% | +$2.85M |
|
261
Strategy Inc
MSTR
$33.5B
| $4.71M | 0.09% |
369,180
+28,300
| +8% | +$411K |
|
|
FNFV
262
DELISTED
Fidelity Natl Financial, Inc.
FNFV
| $4.71M | 0.09% |
+274,956
| New | +$4.57M |
|
263
Douglas Emmett
DEI
$2.06B
| $4.62M | 0.09% |
117,167
-190
| -0.2% | -$7.28K |
|
264
QuidelOrtho
QDEL
$1.09B
| $4.6M | 0.09% |
104,880
+8,480
| +9% | +$295K |
|
265
Lam Research
LRCX
$382B
| $4.58M | 0.09% |
247,530
-45,900
| -16% | -$745K |
|
266
Biogen
BIIB
$29.9B
| $4.54M | 0.09% |
14,496
-14,583
| -50% | -$4.32M |
|
|
NTRI
267
DELISTED
NutriSystem, Inc.
NTRI
| $4.5M | 0.09% |
80,546
+54,732
| +212% | +$2.96M |
|
|
TPC
268
Tutor Perini Cor
TPC
$4.57B
| $4.49M | 0.09% |
158,241
-3,530
| -2% | -$94.9K |
|
269
Avient
AVNT
$3.45B
| $4.43M | 0.09% |
110,755
+16,490
| +17% | +$615K |
|
|
MNDT
270
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $4.42M | 0.09% |
263,686
+48,566
| +23% | +$746K |
|
271
Super Micro Computer
SMCI
$19.5B
| $4.39M | 0.09% |
1,986,890
-57,300
| -3% | -$147K |
|
|
TOWR
272
DELISTED
Tower International, Inc.
TOWR
| $4.38M | 0.09% |
161,035
-9,100
| -5% | -$212K |
|
273
Manitowoc
MTW
$516M
| $4.31M | 0.08% |
+119,648
| New | +$3.48M |
|
274
Moog Inc Class A
MOG.A
$13B
| $4.29M | 0.08% |
51,479
+17,969
| +54% | +$1.36M |
|
275
Astronics
ATRO
$3.45B
| $4.28M | 0.08% |
198,520
+40,034
| +25% | +$817K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2017 Portfolio in Review
As of Q3 2017, Jacobs Levy Equity Management held 1,074 positions worth $5.14B, up 10% from $4.68B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jacobs Levy Equity Management deployed $273M of net new capital in Q3 2017, opening 159 new positions and adding to 412 existing holdings. Its largest new stake was Allergan plc: 114,141 shares worth $23.4M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Intuit, an estimated $26.1M trimmed.
- Jacobs Levy Equity Management's largest Q3 2017 buy was Allergan plc: 114,141 shares worth $23.4M.
- Jacobs Levy Equity Management added most to Philip Morris in Q3 2017, an estimated $28.6M increase.
- Jacobs Levy Equity Management's biggest Q3 2017 reduction was Intuit, cutting an estimated $26.1M.
- Jacobs Levy Equity Management fully exited BWX Technologies in Q3 2017, selling an estimated $13.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 11% of its $5.14B portfolio in Q3 2017.
- Jacobs Levy Equity Management opened 159 new positions and closed 136 in Q3 2017.
- Jacobs Levy Equity Management's portfolio value rose 10% quarter-over-quarter to $5.14B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2017, filed 14 Nov 2017.